Sun Pharma launched Drizalma Sprinkle for treatment of various disorders
A subsidiary of Sun Pharma launched Drizalma Sprinkle in the United States. It is the first and only USFDA approved sprinkle formulation of Drizalma Sprinkle which is delayed-release duloxetine capsules used in treatment of patients suffering from neuro-psychiatric and/or pain disorder accompanied with difficulty swallowing.
Sprinkle formulations are drug-containing pellets or granules which can be mixed with soft food or other contents before administration thus providing a flexibility and convenience of dosage administration to patients with dysphagia. Drizalma Sprinkle which is a serotonin and norepinephrine reuptake inhibitor (SNRI) is indicated for treatment of major depressive disorder (MDD) in adults, generalized anxiety disorder (GAD) in adults and also in pediatric patients, diabetic peripheral neuropathic pain (DPNP) in adults and chronic musculoskeletal pain in adults. The formulation of duloxetine can be swallowed whole, administered via nasogastric tube or sprinkled on applesauce. The drug is available in four dosage strengths as 20mg, 30mg, 40mg, and 60mg. Apart from Drizalma Sprinkle, Sun Pharma has launched Ezallor Sprinkle (Rosuvastatin) and Kapspargo Sprinkle (metoprolol succinate) extended-release capsules as part of its sprinkle formulations drugs portfolio with keeping in focus the treatment needs for individuals in long-term care.
Abhay Gandhi, CEO of Sun Pharma (North America) stated that the company has been able to achieve an important milestone to facilitate the treatment of 30-35 percent of individuals having difficulty in swallowing and suffering from common neuro-psychiatric disorders all the while preserving the quality of the medicine.
Sun Pharmaceutical Industries Limited is manufacturer and seller of pharmaceutical formulations and active pharmaceutical ingredients (APIs) mainly in India and the United States.
On Wednesday, the stock was trading at Rs. 398.30, up by 0.43 per cent or Rs. 1.70 per share. The 52-week high is Rs. 616.50 and 52-week low is Rs. 350.40 on BSE.